Clinical Trial Update: Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI in patients with persistent asthma completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Asthma

Drugs mentioned

• Fluticasone Propionate MDPI (multidose dry powder inhaler) (Fluticasone propionate)
• Fluticasone Propionate/Salmeterol MDPI (Fluticasone propionate / salmeterol)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Persistent Asthma | Phase 3 | Status: COMPLETED | Results posted: 2017-04-14